Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2176
Vanguard Morningstar Value ETF
VTV
$188B
| $1.8M | ﹤0.01% |
10,200
-12,000
| -54% | -$2.03M |
2024 Q3
3 quarters
|
|
2177
Mid Penn Bancorp
MPB
$909M
| $1.8M | ﹤0.01% |
63,898
+13,340
| +26% | +$360K |
2024 Q3
3 quarters
|
|
2178
BayCom
BCML
$335M
| $1.79M | ﹤0.01% |
64,600
-6,600
| -9% | -$174K |
2022 Q2
12 quarters
|
|
2179
Lineage Cell Therapeutics
LCTX
$230M
| $1.79M | ﹤0.01% |
1,972,335
-319,046
| -14% | -$189K |
2023 Q2
8 quarters
|
|
2180
Hingham Institution for Saving
HIFS
$638M
| $1.79M | ﹤0.01% |
7,189
-800
| -10% | -$193K |
2015 Q1
41 quarters
|
|
2181
DELISTED
Apogee Therapeutics
APGE
| $1.78M | ﹤0.01% |
+41,100
| New | +$1.56M |
2025 Q2
0 quarters
|
|
2182
LCNB Corp
LCNB
$266M
| $1.78M | ﹤0.01% |
122,816
-2,800
| -2% | -$40.6K |
2013 Q4
46 quarters
|
|
2183
Vanguard S&P 500 Growth ETF
VOOG
$28.3B
| $1.78M | ﹤0.01% |
+27,000
| New | +$1.61M |
2025 Q2
0 quarters
|
|
2184
Lindblad Expeditions
LIND
$2.38B
| $1.78M | ﹤0.01% |
152,799
-28,500
| -16% | -$282K |
2024 Q1
5 quarters
|
|
2185
DELISTED
First Savings Financial Group
FSFG
| $1.78M | ﹤0.01% |
71,052
+19,352
| +37% | +$496K |
2019 Q1
25 quarters
|
|
2186
Materialise
MTLS
$468M
| $1.78M | ﹤0.01% |
314,300
+200
| +0.1% | +$1.03K |
2021 Q4
14 quarters
|
|
2187
Zentalis Pharmaceuticals
ZNTL
$227M
| $1.77M | ﹤0.01% |
1,529,553
+703,512
| +85% | +$928K |
2023 Q1
9 quarters
|
|
2188
Oceaneering
OII
$4.46B
| $1.77M | ﹤0.01% |
85,600
+31,500
| +58% | +$607K |
2024 Q4
2 quarters
|
|
2189
Coffee Holding Co
JVA
$26M
| $1.77M | ﹤0.01% |
409,592
-19,072
| -4% | -$70.3K |
2014 Q3
43 quarters
|
|
2190
Virco
VIRC
$102M
| $1.77M | ﹤0.01% |
222,111
+2,100
| +1% | +$18.5K |
2013 Q2
48 quarters
|
|
2191
AmeriServ Financial
ASRV
$73.9M
| $1.77M | ﹤0.01% |
582,776
+12,602
| +2% | +$32.5K |
2013 Q2
48 quarters
|
|
2192
Global X Silver Miners ETF NEW
SIL
$4.26B
| $1.77M | ﹤0.01% |
+36,700
| New | +$1.57M |
2025 Q2
0 quarters
|
|
2193
DELISTED
Jamf
JAMF
| $1.76M | ﹤0.01% |
185,400
+42,465
| +30% | +$456K |
2022 Q2
12 quarters
|
|
2194
Valero Energy
VLO
$131B
| $1.76M | ﹤0.01% |
13,100
-104,900
| -89% | -$13.1M |
2025 Q1
1 quarter
|
|
2195
WisdomTree Japan Hedged Equity Fund
DXJ
$2.38B
| $1.76M | ﹤0.01% |
46,200
-5,100
| -10% | -$186K |
2025 Q1
1 quarter
|
|
2196
MFA Financial
MFA
$677M
| $1.76M | ﹤0.01% |
185,950
-153,875
| -45% | -$1.45M |
2020 Q4
18 quarters
|
|
2197
Alector
ALEC
$209M
| $1.76M | ﹤0.01% |
1,254,850
+220,995
| +21% | +$277K |
2021 Q4
14 quarters
|
|
2198
Journey Medical
DERM
$160M
| $1.75M | ﹤0.01% |
243,500
+5,500
| +2% | +$38K |
2023 Q2
8 quarters
|
|
2199
So-Young International
SY
$267M
| $1.75M | ﹤0.01% |
563,228
-18,000
| -3% | -$17.7K |
2020 Q1
21 quarters
|
|
2200
Ingevity
NGVT
$2.41B
| $1.74M | ﹤0.01% |
40,400
+7,300
| +22% | +$282K |
2025 Q1
1 quarter
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.